Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Core Insights - Achieve Life Sciences has promoted Ms. Jaime Xinos to Chief Commercial Officer to lead the commercial operations and strategic preparations for the anticipated U.S. launch of cytisinicline, a treatment for nicotine dependence [1][2][3] Company Overview - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline, targeting the nicotine addiction epidemic, with approximately 29 million adults in the U.S. smoking combustible cigarettes [4] - The company aims to address the health impacts of tobacco use, which is responsible for over eight million deaths worldwide annually, including nearly half a million in the U.S. [4] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, potentially aiding in smoking and e-cigarette cessation by reducing cravings and the satisfaction associated with nicotine [5] - Currently, there are no FDA-approved treatments specifically for e-cigarette cessation, highlighting a significant market opportunity for cytisinicline [4][5] Leadership and Strategy - Ms. Xinos brings nearly 25 years of experience in the biotechnology and pharmaceutical industries, having held leadership roles at major companies such as Pfizer and Novartis [3] - The company plans to forge strategic partnerships with commercialization experts to navigate the challenges faced by small biotech firms launching their first product [2][3]